Microfluidic Organ-on-a-Chip Devices for Liver Disease Modeling In Vitro
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Mortality from liver disease conditions continues to be very high. As liver diseases manifest and progress silently, prompt measures after diagnosis are essential in the treatment of these conditions. Microfluidic organs-on-chip platforms have significant potential for the study of the pathophysiology of liver diseases in vitro. Different liver-on-a-chip microphysiological platforms have been reported to study cell-signaling pathways such as those activating stellate cells within liver diseases. Moreover, the drug efficacy for liver conditions might be evaluated on a cellular metabolic level. Here, we present a comprehensive review of microphysiological platforms used for modelling liver diseases. First, we briefly introduce the concept and importance of organs-on-a-chip in studying liver diseases in vitro, reflecting on existing reviews of healthy liver-on-a-chip platforms. Second, the techniques of cell cultures used in the microfluidic devices, including 2D, 3D, and spheroid cells, are explained. Next, the types of liver diseases (NAFLD, ALD, hepatitis infections, and drug injury) on-chip are explained for a further comprehensive overview of the design and methods of developing liver diseases in vitro. Finally, some challenges in design and existing solutions to them are reviewed
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714 · cited 1×
“In developing countries, the primary cause of liver disease is hepatitis infections, which can be prevented and treated, but in limited availability [3].”
BackgroundThree-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · cited 2×
“Next, scientists work on preparation of media that would be universal for multiple types of cells and mimic the blood [18].”
BackgroundAdvances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Alcoholic Liver Disease: Pathogenesis and Current Management
Osna, N. (2017) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v38.2.01 · Cited by 724 · cited 1×
“It develops in 90% of individuals who consume 4–5 standard doses per day for a long-term perspective (standard dose = 14 g of pure alcohol) and more quickly among binge drinkers [65].”
BackgroundA liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 1×
“However, metabolic activity and function of cells including the production of albumin are reported to vary over time [94,95].”
BackgroundMulti-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Lee, S.-A., No, D. Y., Kang, E., Ju, J., Kim, D.-S., & Lee, S.-H. (2013) · Lab on a Chip · doi:10.1039/c3lc50197c · Cited by 297
Esch, M. B., Mahler, G. J., Stokol, T., & Shuler, M. L. (2014) · Lab Chip · doi:10.1039/c4lc00371c · Cited by 281
3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection
Ortega-Prieto, A. M., Skelton, J. K., Wai, S. N., Large, E., Lussignol, M., Vizcay-Barrena, G., Hughes, D., Fleck, R. A., Thursz, M., Catanese, M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02969-8 · Cited by 236
Cell sources for in vitro human liver cell culture models
Zeilinger, K., Freyer, N., Damm, G., Seehofer, D., & Knöspel, F. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216657448 · Cited by 230
Wang, Y., Wang, H., Deng, P., Chen, W., Guo, Y., Tao, T., & Qin, J. (2018) · Lab on a Chip · doi:10.1039/c8lc00869h · Cited by 222 · cited 1×
“, where cell injury was evaluated by cell viability assay and functionality of CYP family of enzymes [81].”
MethodLong‐term maintenance of a microfluidic 3D human liver sinusoid
Prodanov, L., Jindal, R., Bale, S. S., Hegde, M., McCarty, W. J., Golberg, I., Bhushan, A., Yarmush, M. L., & Usta, O. B. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25700 · Cited by 214
A lung/liver-on-a-chip platform for acute and chronic toxicity studies
Bovard, D., Sandoz, A., Luettich, K., Frentzel, S., Iskandar, A., Marescotti, D., Trivedi, K., Guedj, E., Dutertre, Q., Peitsch, M. C., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc01029c · Cited by 195
Delon, L. C., Guo, Z., Oszmiana, A., Chien, C.-C., Gibson, R., Prestidge, C., & Thierry, B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119521 · Cited by 171
Liver-on-a-Chip models of fatty liver disease
Hassan, S., Sebastian, S., Maharjan, S., Lesha, A., Carpenter, A., Liu, X., Xie, X., Livermore, C., Zhang, Y. S., & Zarrinpar, A. (2020) · Hepatology · doi:10.1002/hep.31106 · Cited by 127 · cited 1×
“reviewed the importance of different cells in the construction of liver-on-chip-platforms and metabolic zonation within the liver [19].”
BackgroundChallenges and Opportunities in the Design of Liver-on-Chip Microdevices
Ehrlich, A., Duche, D., Ouedraogo, G., & Nahmias, Y. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-060418-052305 · Cited by 125
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121 · cited 6×
“For example, monocultures lack interaction with nonparenchymal cells, limited in control of uniformity in the generation of spheroids and organoids [8].”
BackgroundInfluentialMicrofluidic devices for in vitro studies on liver drug metabolism and toxicity
van Midwoud, P. M., Verpoorte, E., & Groothuis, G. M. M. (2011) · Integrative Biology · doi:10.1039/c0ib00119h · Cited by 115
Ho, W. J., Pham, E. A., Kim, J. W., Ng, C. W., Kim, J. H., Kamei, D. T., & Wu, B. M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01723.x · Cited by 115 · cited 2×
“Although spheroids can exist in plates where they were generated, some studies reported that incorporation into scaffolds increases the efficacy in designing tumor models [35].”
BackgroundModeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
Human Nonalcoholic Steatohepatitis on a Chip
Freag, M. S., Namgung, B., Reyna Fernandez, M. E., Gherardi, E., Sengupta, S., & Jang, H. L. (2021) · Hepatology Communications · doi:10.1002/hep4.1647 · Cited by 102 · cited 3×
“(B) NASH-on-chip, prepared with hydrogel channel with hepatic, Kupffer and stellate cells [55] (reproduced with permission from Freag et al.”
BackgroundMethodModeling alcohol-associated liver disease in a human Liver-Chip
Nawroth, J. C., Petropolis, D. B., Manatakis, D. V., Maulana, T. I., Burchett, G., Schlünder, K., Witt, A., Shukla, A., Kodella, K., Ronxhi, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109393 · Cited by 88 · cited 2×
“, the ECM scaffolding was conducted to improve the integrity of bile canaliculi structure, which further allowed to track alteration in canaliculi network in response to alcohol exposure in microfluidic devices as shown in Figure 3A (2021) [67].”
MethodTeng, Y., Zhao, Z., Tasnim, F., Huang, X., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120904 · Cited by 62
Suurmond, C. E., Lasli, S., van den Dolder, F. W., Ung, A., Kim, H., Bandaru, P., Lee, K., Cho, H., Ahadian, S., Ashammakhi, N., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901379 · Cited by 61
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02616-x · Cited by 52 · cited 2×
“The three-culture spheroid microphysiological platform was used to induce the NAFLD with progression to NASH by measuring the deposition of the collagen and markers of fibrotic tissue [63].”
BackgroundMethodMicrofluidic platform for hepatitis B viral replication study
Sodunke, T. R., Bouchard, M. J., & Noh, H. (. (2008) · Biomedical Microdevices · doi:10.1007/s10544-007-9148-1 · Cited by 38 · cited 2×
“Later devices implemented more complex designs with greater number of cells cell types used in studies [73].”
BackgroundMethod
Cited by
Modelling and targeting mechanical forces in organ fibrosis
Mascharak, S., L. Guo, J., Griffin, M., E. Berry, C., C. Wan, D., & T. Longaker, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00144-3 · Cited by 59
“Two-dimensional fluidic flow models have yielded fundamental insights into the cellular machinery by which endothelial, hepatocyte, immune and other cell types respond to homeostatic and disturbed fluidic flow conditions 109 .”
Microfluidic systems for modeling digestive cancer: a review of recent progress
Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Dabagh, M. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad6f15 · Cited by 24
A high-throughput microphysiological system to quantify key events leading to liver fibrosis
Schmidt, S., & Suter-Dick, L. (2025) · Toxicology · doi:10.1016/j.tox.2025.154248 · Cited by 3
Metadata
- Authors
- Kanabekova, P., Kadyrova, A., & Kulsharova, G.
- Venue
- Micromachines
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 13
- Issue
- 3
- Pages
- 428
- ISSN
- 2072-666X (ISSN-L)
- OpenAlex
- W4220880013
- Cited by
- 70
- References
- 35
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.